PCI Biotech Holding ASA (OSL:PCIB)
0.2810
-0.0220 (-7.26%)
Oct 3, 2025, 4:17 PM CET
PCI Biotech Holding ASA Revenue
PCI Biotech Holding ASA had revenue of 1.38M NOK in the half year ending June 30, 2025, with 230.70% growth. This brings the company's revenue in the last twelve months to 4.69M, down -21.85% year-over-year. In the year 2024, PCI Biotech Holding ASA had annual revenue of 6.74M with 125.25% growth.
Revenue (ttm)
4.69M
Revenue Growth
-21.85%
P/S Ratio
2.24
Revenue / Employee
937.60K
Employees
5
Market Cap
10.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.74M | 3.75M | 125.25% |
Dec 31, 2023 | 2.99M | -1.76M | -37.05% |
Dec 31, 2022 | 4.75M | -1.52M | -24.28% |
Dec 31, 2021 | 6.27M | -1.10M | -14.86% |
Dec 31, 2020 | 7.37M | -2.02M | -21.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Medistim ASA | 628.08M |
Nordhealth AS | 578.17M |
Photocure ASA | 522.86M |
ArcticZymes Technologies ASA | 104.33M |
Omda AS | 458.96M |
Vistin Pharma ASA | 452.25M |
Gentian Diagnostics ASA | 163.38M |
Nykode Therapeutics AS | 79.85M |